Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose study of subcutaneous MLN1202 in healthy Japanese and Caucasian males
jRCT2080222822Phase 1
- Sponsor
- Takeda
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of plozalizumab (12 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of single subcutaneous doses of MLN1202, Pharmacokinetics of MLN1202 and 1 more.
02
Drugs
plozalizumab
Beyond the preview
Go deeper on jRCT2080222822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222822.